TransGenic Group

TransGenic Group Profit per Employee

The Profit per Employee of TransGenic Group (2342.T) as of Nov 11, 2026 is -327,406.78 JPY. In the previous year, Profit per Employee was -4.62 M JPY — a change of -92.91% (higher).

Profit per Employee

-327,406.78JPY

YoY

-92.91%

Last updated:

Profit per Employee of TransGenic Group is 2026 -327,406.78 JPY. Profit per Employee of TransGenic Group was 2025 -4.62 M JPY. It decreases by -92.91% higher compared to the previous year.

The TransGenic Group Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2019
856,860.17 JPY
Jan 1, 2020
-1.87 M JPY
Jan 1, 2021
2.31 M JPY
Jan 1, 2022
7.95 M JPY
Jan 1, 2023
-1.74 M JPY
Jan 1, 2024
17,309.32 JPY
Jan 1, 2025
-4.62 M JPY
Jan 1, 2026
-327,406.78 JPY
The TransGenic Group Profit per Employee history
YEARProfit per EmployeeYoY
-327,406.78JPY-92.91%
-4.62 MJPY-26,774.22%
17,309.32JPY-101.00%
-1.74 MJPY-121.83%
7.95 MJPY+243.47%
2.31 MJPY-223.96%
-1.87 MJPY-317.94%
856,860.17JPY+867.65%
88,550.85JPY-74.10%
341,923.73JPY+453.19%
61,809.32JPY-18.16%
75,525.42JPY-115.68%
-481,533.90JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Profit per Employee of TransGenic Group is -327,406.78 JPY in 2026.

Profit per Employee of TransGenic Group changed from -4.62 M JPY to -327,406.78 JPY, representing a -92.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's TransGenic Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — TransGenic Group

All Key Metrics — TransGenic Group